Akèy › Kansè pwostat › Pennsylvania › Philadelphia
Etid klinik pou Kansè pwostat nan Philadelphia, PA
44 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Philadelphia (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Ap rekriteFaz 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · 13 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · 22 mi lwen
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Ap rekriteFaz 1
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Philadelphia
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- Fox Chase Cancer Center ( Site 0076), Philadelphia
- MidLantic urology ( Site 0022), Bala-Cynwyd · 5 mi lwen
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- MidLantic urology, Bala-Cynwyd · 5 mi lwen
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Ap rekriteFaz 2/3
- Fox Chase Cancer Center, Philadelphia
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Ap rekriteFaz 2
- Philadelphia MultiService Center, Philadelphia, PA, Philadelphia
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- Perelman Center for Advanced Medicine ( Site 0067), Philadelphia
- Abramson Cancer Center - Penn Medicine ( Site 0079), Philadelphia
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Ap rekriteFaz 1/2
- GSK Investigational Site, Philadelphia
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
- Thomas Jefferson University, Philadelphia
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Ap rekrite
- MidLantic Urology, Bala-Cynwyd · 5 mi lwen
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi lwen
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi lwen
A Study of Tarlatamab for People With Prostate Cancer
Ap rekriteFaz 2
- Thomas Jefferson University Hospital, Philadelphia
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Thomas Jefferson University, Philadelphia
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Ap rekriteFaz 2
- Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- Penn Presbyterian Medical Center, Philadelphia
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
- Thomas Jefferson University Honickman Center, Philadelphia
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Ap rekriteFaz 1
- Thomas Jefferson University, Philadelphia
PSMA PET Combined With MRI for the Detection of PCa
Ap rekriteFaz 3Volontè an sante akeyi
- MidLantic Urology, Philadelphia
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #109, Philadelphia
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Philadelphia Veterans Administration Medical Center, Philadelphia
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi lwen
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi lwen
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- MidLantic Urology, Bala-Cynwyd · 5 mi lwen
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Ap rekriteFaz 1
- Thomas Jefferson University, Philadelphia
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Ap rekriteFaz 1/2
- Thomas Jefferson University Hospital, Philadelphia
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Ap rekriteFaz 2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia
TERPS Trial for de Novo Oligometastic Prostate Cancer
Ap rekriteFaz 2
- Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Ap rekriteEtid obsèvasyon
- Fox Chase Cancer Center - Temple Health, Philadelphia
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Ap rekrite
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Philadelphia
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Hypofractionated WPPT With HDR Boost
Ap rekriteFaz 2
- University of Pennsylvania, Philadelphia
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- MidLantic Urology, Bala-Cynwyd · 5 mi lwen
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- Albert Einstein Healthcare Network, Philadelphia
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Ap rekriteFaz 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi lwen
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi lwen
Prostate Tissue BioBank
Ap rekriteEtid obsèvasyon
- University of Pennsylvania, Philadelphia
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
Ap rekrite
- Fox Chase Cancer Center, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Philadelphia
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Baltimore, MD43 etid
- Nashville, TN43 etid
- Seattle, WA42 etid
- Washington, DC38 etid
- Dallas, TX36 etid
Lòt etid nan Philadelphia
- Kansè (tout kalite)59 etid
- Kansè nan tete56 etid
- Kansè Poumon ki pa ti selil51 etid
- Kansè Metastatik46 etid
- Kansè kolorektal44 etid
- Kansè ovè44 etid
- Kansè poumon36 etid
- Leksemi mieloïd egi34 etid
- Ensifizyans kadyak31 etid
- Kansè Endomèt28 etid
- Depresyon26 etid
- Kansè pankreyas26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.